Quantcast

Latest Head and neck cancer Stories

2012-06-04 19:36:53

Skin cancer patients whose childhood included periods of neglect or maltreatment are at a much greater risk for their cancers to return when they face a major stressful event, based on a new study. The research suggests that such experiences during a person's youth can set a lower level of immune response for life, which in turn might make them more susceptible to the kind of cancers that are often successfully fought by the immune system, so-called immunogenic tumors. While the...

2012-05-31 12:49:01

Younger patients with colorectal cancer were more likely to present advanced stage tumors at diagnosis and metastasize much sooner, yet had better than or equal survival to patients 50 and older, according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract #3621, Monday, June 4, 8:00 AM - 12:00 PM CST, S Hall A2). The study was led by Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson...

2012-05-17 23:03:57

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, HPV-positive head and neck cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago. New York, NY (PRWEB) May 17, 2012 Mount Sinai School of Medicine researchers will present several landmark studies,...

2012-05-17 14:18:12

Landmark research presented at annual cancer meeting Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago. Highlights of Mount Sinai research at ASCO: Age, Race, Lower Income, and Lack of...

2012-05-17 12:41:57

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas – the most common type of non-small cell lung cancer – and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung...

2012-05-17 09:26:40

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib. Findings from this phase I study will be presented at the American Society of Clinical Oncology annual meeting in...

2012-05-15 12:44:25

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily. The findings provide valuable insight as to why some cancers metastasize to bone, and could eventually result in new metastasis-prevention drugs, said Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry and principal...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related